ライフサイエンスコーパス: alloimmunized

1 (15%) episodically transfused patients were alloimmunized.

2 14 (22%) of 64 patients (75% Asian) became alloimmunized.

3 on chronic RBC transfusion remained platelet-alloimmunized 11 to 22 months after initial testing.

4 patible red blood cells for patients who are alloimmunized against multiple antigens.

5 l of T cell polarization will differ between alloimmunized and non-alloimmunized SCD patients.

6 for the detection of fetal antigens for both alloimmunized and RhD-negative non-alloimmunized pregnan

7 To overcome the alloimmunized B-cell heme insensitivity, we screened sev

8 cyte transfusion recipients were found to be alloimmunized both to neutrophil-specific and HLA antige

9 transfusion, whereas others not only become alloimmunized but may also be prone to generating additi

10 CD4 and CD8 memory T cells were sorted from alloimmunized CXCR3 and wildtype B6 mice and cotransferr

11 KO mice lacking both FcgammaRs and C3 became alloimmunized despite immunoprophylaxis.

12 the peripheral blood lymphocytes of a single alloimmunized donor.

13 ma and apheresis platelets, from potentially alloimmunized donors, especially females.

14 or male recipients of a marrow graft from an alloimmunized female.

15 nhibited by exogenous heme, B cells from the alloimmunized group were nonresponsive to heme inhibitio

16 D group, whereas it had little effect in the alloimmunized group.

17 n-alloimmunized SCD patients, but not in the alloimmunized group.

18 re effective products for difficult, broadly alloimmunized individuals, including patients who have d

19 However, in alloimmunized lymphocytoxic antibody-positive patients,

20 tions and infusions, patients who are highly alloimmunized may be deemed ineligible.

21 e therefore reviewed the results of OAMPT to alloimmunized patients and assessed the relationship bet

22 selection and transfusion support for highly alloimmunized patients and for confirmation of A2 status

23 ificant and can result in transplantation of alloimmunized patients considered to be non-sensitized.

24 platelet donor pool, significant numbers of alloimmunized patients have few if any available donors.

25 from nonmatched ABO compatible donors, while alloimmunized patients should receive granulocytes from

26 se data support extending donor searches for alloimmunized patients to include any single mismatch pa

27 er to determine platelet compatibility in 16 alloimmunized patients with aplastic anemia refractory t

28 level of LCTAB and the response of OAMPT to alloimmunized patients, 58% to 73% of recipients will ha

29 An approach more like that for red cell alloimmunized patients, in which one provides products g

30 These data suggest that unlike alloimmunized patients, non-alloimmunized SCD CD16+ mono

31 Originally designed for highly alloimmunized patients, this algorithm is based on the c

32 to refine and expand donor selection for HLA-alloimmunized patients.

33 latelets should be considered to support HLA alloimmunized patients.

34 oduce an alternative source of rare RBCs for alloimmunized patients.

35 ersing the resistance to heme suppression in alloimmunized patients.

36 Alloimmunized, platelet-refractory, thrombocytopenic pat

37 vent fetal intracranial hemorrhage in HPA-1a alloimmunized pregnancies, we generated an antibody that

38 tions, NIPT has become essential in managing alloimmunized pregnancies.

39 loimmunized pregnant people and 0.1% for 769 alloimmunized pregnancies.

40 individuals and 93 antigen evaluations in 30 alloimmunized pregnancies.

41 approach to the management of red blood cell alloimmunized pregnancies.

42 for both alloimmunized and RhD-negative non-alloimmunized pregnant individuals may streamline care a

43 results rate was 0% for 711 RhD-negative non-alloimmunized pregnant people and 0.1% for 769 alloimmun

44 tly, the adoptive transfer of monocytes from alloimmunized RAG(-/-) mice conferred alloimmunity to na

45 l donors and by histocompatibility issues in alloimmunized recipients.

46 Non-alloimmunized SCD CD16+ monocytes expressed higher basal

47 gest that unlike alloimmunized patients, non-alloimmunized SCD CD16+ monocytes in response to transfu

48 reg/lower Th1) polarization state in the non-alloimmunized SCD group, whereas it had little effect in

49 hemin-treated stimulated monocytes from non-alloimmunized SCD patients, but not in the alloimmunized

50 ed B cells in nonalloimmunized compared with alloimmunized SCD patients.

51 on will differ between alloimmunized and non-alloimmunized SCD patients.

52 , 85% of heavily transfused SCD patients are alloimmunized to HLA and/or platelet-specific antigens.

53 Factors regulating which patients become alloimmunized to red blood cell (RBC) antigens are poorl

54 the policies of avoiding prospective donors alloimmunized to WBC antigens from donating plasma produ

55 onor specific antibody (DSA) in the serum of alloimmunized transplant patients with a failed renal gr

56 in two positive control donors who had been alloimmunized with Rh D-positive RBCs.

57 nce which transfusion recipients will become alloimmunized, with genetic as well as innate/adaptive i

58 derived from an immortalized B cell from an alloimmunized woman who had an infant affected by FNAIT.

59 C terminus elicited proliferation in 90% of alloimmunized women, and it was confirmed that respondin